Celldex Therapeutics Inc (CLDX) 28.95 $CLDX
Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies
GlobeNewswire - Mon Apr 20, 7:01AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today preclinical results that further support varlilumab's expansion into combination studies with PD-1 inhibitors. The data were presented in a poster session entitled "Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site" at the 2015 American Association for Cancer Research Annual Meeting.
CLDX: 28.95 (+1.08)
Global Cancer Growth Inhibitors Market & Clinical Pipeline Analysis 2015
M2 - Thu Apr 16, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrxk42/cancer_growth) has announced the addition of the "Cancer Growth Inhibitors Market & Clinical Pipeline Analysis " report to their offering. Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth. Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology. Cancer Growth Inhibitors Covered in Report: - Cancer Tyrosine Kinase - Proteasome Inhibitors - MTOR Protein Inhibitors - Histone Deacetylase Inhibitors (HDAC inhibitors) - PI3k Cancer Growth Inhibitors Market & Clinical Pipeline Analysis Report Highlight: - Introduction & Classification of Cancer Growth Inhibitors - Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase - Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs - Markets Cancer Growth Inhibitors: 48 Drugs - Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs - HDAC Inhibitors Clinical Pipeline: 65 Drugs - MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs - PI3k Clinical Pipeline: 89 Drugs - Proteasome Inhibitors Clinical Pipeline: 19 Drugs - Global Cancer Growth Inhibitors Market Future Prospects Companies Mentioned - Advaxis - Amgen - AstraZeneca - Bristol Mayer Squibb - Celldex Therapeutics - Eli Lily - GalaxoSmithKline - Genetech.ImmunoCellular Therapeutics - ImmunoGen - Merck - Novartis - Pfizer - Roche - Sanofi - Teva For more information visit http://www.researchandmarkets.com/research/zr...cer_growth
MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), AMGN: 169.10 (+0.64), NVS: 103.45 (-0.62)
Celldex Therapeutics Pushes Forward With Varlilumab And Further Proves Its Worth
Investing Healthcare - at Seeking Alpha - Tue Apr 14, 10:05AM CDT
KITE: 57.56 (-1.43), CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21), ONTY: 1.80 (+0.03)
Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 3:49PM CDT
Exelixis' (EXEL) lead drug Cometriq gets fast-track status in the U.S. for the treatment of kidney cancer.
CBM: 42.07 (-0.65), CLDX: 28.95 (+1.08), EXEL: 3.12 (+0.05)
Cancer Targeted Therapy Market & Clinical Insight 2015
M2 - Thu Apr 09, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq2wq/cancer_targeted) has announced the addition of the "Cancer Targeted Therapy Market & Clinical Insight 2015" report to their offering. Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles. Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report: - Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI - Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors - Cancer Vaccines Pipeline: 289 Cancer Vaccines - Cancer Targeted Monoclonal Antibodies: 605 mAb - Oncogene Inhibitors Pipeline: 185 oncogene inhibitors Cancer Targeted Therapy Market & Clinical Insight Report Highlight: - Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies Key Topics Covered: 1. Introduction to Cancer Targeted Therapeutics 2. Need for Cancer Targeted Therapeutics 3. Categorization of Cancer Targeted Therapies 4. Consideration of Cancer Vaccines as Targeted Therapeutics 5. Mechanism of Cancer Vaccines 6. Mechanisms of Cancer Targeted Monoclonal Antibodies 7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics 8. Mechanism of Oncogene Inhibitors 9. Global Cancer Targeted Therapy Market Overview 10. Global Cancer Targeted Therapeutics Market Dynamics 11. Future Prospects of Cancer Targeted Therapeutics 12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase 13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase 15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 16. Oncogene Inhibitors Pipeline by Company, Indication & Phase 17. Marketed Oncogene Inhibitors by Company & Indication 18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase 19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors 20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication 21. Marketed Cancer Targeted Angiogenesis Inhibitors 22. Competitive Landscape - Advaxis - Bind Therapeutics - Boehringer Ingelheim - Bristol Mayer Squibb - Celldex Therapeutics - Dendreon Corporation - Eli Lily - GalaxoSmithKline - Galena Biopharma - Genetech - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Johnson & Johnson - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Merck - Novartis - Peregrine Pharmaceuticals - Pfizer - Roche - Sanofi - Seattle Genetics - Teva For more information visit http://www.researchandmarkets.com/research/4l...r_targeted
JNJ: 100.43 (+0.13), INO: 10.38 (-0.10), NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), NLNK: 53.12 (-0.07), GALE: 1.39 (unch), IMUC: 0.53 (+0.02), NVS: 103.45 (-0.62)
Celldex Therapeutics
at Investor's Business Daily - Tue Apr 07, 5:53PM CDT
Celldex Therapeutics (CLDX) said that a stage 2 trial showed promising results for its breast-cancer drug glembatumumab vedotin in metastatic breast cancer patients. Shares rose 3.1% to 27.19.
CLDX: 28.95 (+1.08)
Celldex Initiates Study on Varlilumab for Metastatic Melanoma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 4:14PM CDT
Celldex (CLDX) initiates a phase I/II study to evaluate varlilumab in combination with Bristol-Myers' (BMY) Yervoy and CDX-1401.
CBM: 42.07 (-0.65), CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21)
Stocks Lose Gains; Twitter Reportedly Takeover Target
at Investor's Business Daily - Tue Apr 07, 3:31PM CDT
Stocks sold off in the final hour of trade to finish lower after spending most of the day in positive territory. Volume was slightly higher on the Nasdaq and lower on the New York Stock Exchange, according to preliminary data. The S&P 500 eased 0.1%,...
FDX: 170.01 (+0.10), GS: 198.32 (+1.48), FB: 84.63 (+1.01), CLDX: 28.95 (+1.08), GM: 37.16 (unch), XOM: 87.46 (+0.58), GOOGL: 549.18 (+6.26), CVX: 109.50 (-0.23), TWTR: 51.73 (+0.41), AAPL: 128.62 (+1.71)
Stocks Trade Higher; GM Drops As Canada Sells Shares
at Investor's Business Daily - Tue Apr 07, 2:01PM CDT
Stocks traded quietly, holding most of the day's gains with an hour left in the session. Volume was tracking slightly higher on the Nasdaq and slightly lower on the New York Stock Exchange. General Motors (GM) lost more than 2%. The Canadian...
FDX: 170.01 (+0.10), GS: 198.32 (+1.48), GBX: 64.37 (+0.56), CLDX: 28.95 (+1.08), GM: 37.16 (unch)
Stocks Hold Gains; Autohome, Twitter Rise
at Investor's Business Daily - Tue Apr 07, 12:31PM CDT
Stocks held moderate gains in early afternoon trading Tuesday. Volume was tracking higher on the Nasdaq and slightly lower on the New York Stock Exchange. The Nasdaq and the Dow Jones industrial average rose 0.5%; the S&P 500 gained 0.3% in the stock...
FDX: 170.01 (+0.10), CLDX: 28.95 (+1.08), HZNP: 30.96 (+0.10), TWTR: 51.73 (+0.41), ATHM: 52.09 (+0.08), HPTX: 45.96 (-0.18)
Celldex Up As Breast-Cancer Drug Shows Promise
at Investor's Business Daily - Tue Apr 07, 10:44AM CDT
Celldex Therapeutics (CLDX) stock was up 6% in morning trading Tuesday after the biotech company updated its midstage trial results on its breast-cancer drug late Monday. Results from the phase-two trial, called Emerge, of glembatumumab vedotin in...
PFE: 34.93 (+0.04), AZN: 73.35 (+0.65), CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21)
Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched
at The Street - Tue Apr 07, 7:02AM CDT
The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.
ADXS: 22.18 (+0.10), MRK: 57.69 (+0.03), INCY: 107.98 (-1.20), CLDX: 28.95 (+1.08), LBIO: 12.50 (+0.50), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21), TWTR: 51.73 (+0.41), NVS: 103.45 (-0.62), CELG: 115.54 (+0.72)
Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer Published in Journal of Clinical Oncology
GlobeNewswire - Mon Apr 06, 3:01PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, including breast cancer. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome.
CLDX: 28.95 (+1.08)
Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma
GlobeNewswire - Mon Apr 06, 7:01AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the initiation of a Phase 1/2 safety pilot and expansion study examining the investigational combination of varlilumab and ipilimumab (Yervoy; Bristol-Myers Squibb) in patients with Stage III or IV metastatic melanoma. Varlilumab is Celldex's fully human monoclonal antibody that targets CD27, a critical co-stimulatory molecule in the immune activation cascade. Ipilimumab, a recombinant, human monoclonal antibody that blocks CTLA-4, is FDA approved for the treatment of unresectable or metastatic melanoma. In the Phase 2 portion of the study, patients with tumors that express NY-ESO-1 will also receive CDX-1401, Celldex's off-the-shelf antibody-based dendritic cell vaccine that targets tumors expressing the NY-ESO-1 oncoprotein.
CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21)
Roth Capital Weighs In On 5 Biotech Stocks To Watch
TipRanks - at Seeking Alpha - Mon Apr 06, 4:02AM CDT
By Sarah Roden As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to "focus on names with definitive catalysts." Though the analyst rates 15 biotech stocks,...
CRIS: 2.88 (+0.09), GNVC: 2.86 (-0.11), CLDX: 28.95 (+1.08), BLRX: 2.12 (unch), KERX: 11.52 (-0.15)
Disruptive Innovation Changing the Fight Against Cancer
Cheryl Swanson, The Motley Fool - Motley Fool - Sun Apr 05, 12:02PM CDT
We all know someone who is battling cancer. It's a terrible disease, with over 1.6 million new cases diagnosed every year in the U.S. Cancer deaths per 100,000 people have been slowly declining since 1991, but tragically, modern treatment often has...
NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), AZN: 73.35 (+0.65), XON: 44.53 (+0.36), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
Smith On Stocks - Seeking Alpha - Tue Mar 31, 8:48AM CDT
Executive Summary Northwest Biotherapeutics (NASDAQ: NWBO ) has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed...
NWBO: 8.36 (-0.39), KITE: 57.56 (-1.43), CLDX: 28.95 (+1.08), JUNO: 55.72 (-0.68)
Celldex: An Immuno-Oncology Play With Monster Potential
DoconStocks - at Seeking Alpha - Mon Mar 30, 5:17PM CDT
CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21)
3 Up and Coming Biotech Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 29, 1:02PM CDT
Source: Ligand Pharmaceuticals How hot is biotech these days? The top two exchange trade funds focusing on biotech stocks both more than tripled the performance of the S&P 500 index over the past 12 months. That's pretty hot. You might be...
PTLA: 38.48 (-0.47), CLDX: 28.95 (+1.08), LGND: 87.71 (-0.58)
Celldex Therapeutics Has Returned 17.6% Since SmarTrend Recommendation (CLDX)
Comtex SmarTrend(R) - Tue Mar 24, 11:34AM CDT
SmarTrend identified an Uptrend for Celldex Therapeutics (NASDAQ:CLDX) on February 23rd, 2015 at $24.52. In approximately 4 weeks, Celldex Therapeutics has returned 17.64% as of today's recent price of $28.84.
CLDX: 28.95 (+1.08)
Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in Preclinical Studies
GlobeNewswire - Mon Apr 20, 7:01AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today preclinical results that further support varlilumab's expansion into combination studies with PD-1 inhibitors. The data were presented in a poster session entitled "Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site" at the 2015 American Association for Cancer Research Annual Meeting.
CLDX: 28.95 (+1.08)
Global Cancer Growth Inhibitors Market & Clinical Pipeline Analysis 2015
M2 - Thu Apr 16, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zrxk42/cancer_growth) has announced the addition of the "Cancer Growth Inhibitors Market & Clinical Pipeline Analysis " report to their offering. Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth. Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology. Cancer Growth Inhibitors Covered in Report: - Cancer Tyrosine Kinase - Proteasome Inhibitors - MTOR Protein Inhibitors - Histone Deacetylase Inhibitors (HDAC inhibitors) - PI3k Cancer Growth Inhibitors Market & Clinical Pipeline Analysis Report Highlight: - Introduction & Classification of Cancer Growth Inhibitors - Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase - Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs - Markets Cancer Growth Inhibitors: 48 Drugs - Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs - HDAC Inhibitors Clinical Pipeline: 65 Drugs - MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs - PI3k Clinical Pipeline: 89 Drugs - Proteasome Inhibitors Clinical Pipeline: 19 Drugs - Global Cancer Growth Inhibitors Market Future Prospects Companies Mentioned - Advaxis - Amgen - AstraZeneca - Bristol Mayer Squibb - Celldex Therapeutics - Eli Lily - GalaxoSmithKline - Genetech.ImmunoCellular Therapeutics - ImmunoGen - Merck - Novartis - Pfizer - Roche - Sanofi - Teva For more information visit http://www.researchandmarkets.com/research/zr...cer_growth
MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), AMGN: 169.10 (+0.64), NVS: 103.45 (-0.62)
Celldex Therapeutics Pushes Forward With Varlilumab And Further Proves Its Worth
Investing Healthcare - at Seeking Alpha - Tue Apr 14, 10:05AM CDT
KITE: 57.56 (-1.43), CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21), ONTY: 1.80 (+0.03)
Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 10, 3:49PM CDT
Exelixis' (EXEL) lead drug Cometriq gets fast-track status in the U.S. for the treatment of kidney cancer.
CBM: 42.07 (-0.65), CLDX: 28.95 (+1.08), EXEL: 3.12 (+0.05)
Cancer Targeted Therapy Market & Clinical Insight 2015
M2 - Thu Apr 09, 5:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq2wq/cancer_targeted) has announced the addition of the "Cancer Targeted Therapy Market & Clinical Insight 2015" report to their offering. Cancer targeted therapeutics global market could be broadly divided into small and large molecules segments. Small molecules generate significant shares due to their sheer numbers as compared to large molecules cancer targeted therapeutics. Moreover, they have mature market and they could be considered as pioneer due to which they have more market penetration across the globe. Their prices have gone down because significant progress has been achieved in their drug design development, manufacturing and marketing. However, they have limited targeting efficacy and limited products could be used for multiple cancer indications. This scenario gave way to market introduction of large molecule cancer targeted therapeutics having better pharmacological profiles. Clinical Insight on Cancer Targeted Therapies Pipeline Covered in Report: - Cancer Targeted Tyrosine Kinase Inhibitors Pipeline: 388 TKI - Cancer Targeted Angiogenesis Inhibitors Pipeline: 166 Angiogenesis Inhibitors - Cancer Vaccines Pipeline: 289 Cancer Vaccines - Cancer Targeted Monoclonal Antibodies: 605 mAb - Oncogene Inhibitors Pipeline: 185 oncogene inhibitors Cancer Targeted Therapy Market & Clinical Insight Report Highlight: - Introduction & Categorization of Cancer Targeted Therapies - Mechanism of Cancer Targeted Tyrosine Kinase, Vaccines, Oncogenes Inhibitors, Monoclonal Antibodies - Cancer Targeted Therapy Clinical Pipeline by Company, Indication & Phase - Clinical Insight on More Than 1200 Cancer Targeted Therapies in Pipeline - Clinical Insight & Patent Analysis of Marketed Cancer Targeted Therapies - Global Cancer Targeted Therapeutics Market Dynamics - Future Prospects of Cancer Targeted Therapies Key Topics Covered: 1. Introduction to Cancer Targeted Therapeutics 2. Need for Cancer Targeted Therapeutics 3. Categorization of Cancer Targeted Therapies 4. Consideration of Cancer Vaccines as Targeted Therapeutics 5. Mechanism of Cancer Vaccines 6. Mechanisms of Cancer Targeted Monoclonal Antibodies 7. Mechanism of Cancer Targeted Tyrosine Kinase Therapeutics 8. Mechanism of Oncogene Inhibitors 9. Global Cancer Targeted Therapy Market Overview 10. Global Cancer Targeted Therapeutics Market Dynamics 11. Future Prospects of Cancer Targeted Therapeutics 12. Cancer Targeted Monoclonal Antibodies Pipeline by Company, Indication & Phase 13. Marketed Cancer Monoclonal Antibodies by Indication, Company & Country 14. Global Cancer Vaccines Clinical Pipeline Insight by Company, Indication & Phase 15. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country 16. Oncogene Inhibitors Pipeline by Company, Indication & Phase 17. Marketed Oncogene Inhibitors by Company & Indication 18. Cancer Targeted Tyrosine Kinase Clinical Trial by Company, Indication & Phase 19. Marketed Cancer Targeted Tyrosine Kinase Inhibitors 20. Cancer Targeted Angiogenesis Inhibitors Therapy Pipeline by Company, Phase & Indication 21. Marketed Cancer Targeted Angiogenesis Inhibitors 22. Competitive Landscape - Advaxis - Bind Therapeutics - Boehringer Ingelheim - Bristol Mayer Squibb - Celldex Therapeutics - Dendreon Corporation - Eli Lily - GalaxoSmithKline - Galena Biopharma - Genetech - ImmunoCellular Therapeutics - ImmunoGen - Inovio Pharmaceuticals - Johnson & Johnson - NeoStem Oncology - NewLink Genetics - Northwest Biotherapeutics - Merck - Novartis - Peregrine Pharmaceuticals - Pfizer - Roche - Sanofi - Seattle Genetics - Teva For more information visit http://www.researchandmarkets.com/research/4l...r_targeted
JNJ: 100.43 (+0.13), INO: 10.38 (-0.10), NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), NLNK: 53.12 (-0.07), GALE: 1.39 (unch), IMUC: 0.53 (+0.02), NVS: 103.45 (-0.62)
Celldex Therapeutics
at Investor's Business Daily - Tue Apr 07, 5:53PM CDT
Celldex Therapeutics (CLDX) said that a stage 2 trial showed promising results for its breast-cancer drug glembatumumab vedotin in metastatic breast cancer patients. Shares rose 3.1% to 27.19.
CLDX: 28.95 (+1.08)
Celldex Initiates Study on Varlilumab for Metastatic Melanoma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 4:14PM CDT
Celldex (CLDX) initiates a phase I/II study to evaluate varlilumab in combination with Bristol-Myers' (BMY) Yervoy and CDX-1401.
CBM: 42.07 (-0.65), CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21)
Stocks Lose Gains; Twitter Reportedly Takeover Target
at Investor's Business Daily - Tue Apr 07, 3:31PM CDT
Stocks sold off in the final hour of trade to finish lower after spending most of the day in positive territory. Volume was slightly higher on the Nasdaq and lower on the New York Stock Exchange, according to preliminary data. The S&P 500 eased 0.1%,...
FDX: 170.01 (+0.10), GS: 198.32 (+1.48), FB: 84.63 (+1.01), CLDX: 28.95 (+1.08), GM: 37.16 (unch), XOM: 87.46 (+0.58), GOOGL: 549.18 (+6.26), CVX: 109.50 (-0.23), TWTR: 51.73 (+0.41), AAPL: 128.62 (+1.71)
Stocks Trade Higher; GM Drops As Canada Sells Shares
at Investor's Business Daily - Tue Apr 07, 2:01PM CDT
Stocks traded quietly, holding most of the day's gains with an hour left in the session. Volume was tracking slightly higher on the Nasdaq and slightly lower on the New York Stock Exchange. General Motors (GM) lost more than 2%. The Canadian...
FDX: 170.01 (+0.10), GS: 198.32 (+1.48), GBX: 64.37 (+0.56), CLDX: 28.95 (+1.08), GM: 37.16 (unch)
Stocks Hold Gains; Autohome, Twitter Rise
at Investor's Business Daily - Tue Apr 07, 12:31PM CDT
Stocks held moderate gains in early afternoon trading Tuesday. Volume was tracking higher on the Nasdaq and slightly lower on the New York Stock Exchange. The Nasdaq and the Dow Jones industrial average rose 0.5%; the S&P 500 gained 0.3% in the stock...
FDX: 170.01 (+0.10), CLDX: 28.95 (+1.08), HZNP: 30.96 (+0.10), TWTR: 51.73 (+0.41), ATHM: 52.09 (+0.08), HPTX: 45.96 (-0.18)
Celldex Up As Breast-Cancer Drug Shows Promise
at Investor's Business Daily - Tue Apr 07, 10:44AM CDT
Celldex Therapeutics (CLDX) stock was up 6% in morning trading Tuesday after the biotech company updated its midstage trial results on its breast-cancer drug late Monday. Results from the phase-two trial, called Emerge, of glembatumumab vedotin in...
PFE: 34.93 (+0.04), AZN: 73.35 (+0.65), CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21)
Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched
at The Street - Tue Apr 07, 7:02AM CDT
The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.
ADXS: 22.18 (+0.10), MRK: 57.69 (+0.03), INCY: 107.98 (-1.20), CLDX: 28.95 (+1.08), LBIO: 12.50 (+0.50), JUNO: 55.72 (-0.68), BMY: 66.60 (-0.21), TWTR: 51.73 (+0.41), NVS: 103.45 (-0.62), CELG: 115.54 (+0.72)
Celldex Therapeutics' Phase 2 EMERGE Study of Glembatumumab Vedotin in Metastatic Breast Cancer Published in Journal of Clinical Oncology
GlobeNewswire - Mon Apr 06, 3:01PM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that data from the Phase 2 EMERGE study of glembatumumab vedotin in metastatic breast cancer have been published in the Journal of Clinical Oncology. The data from this study supported the initiation of the ongoing, pivotal Phase 2 METRIC study in patients with triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a protein expressed by multiple tumor types, including breast cancer. Overexpression of gpNMB has been shown to promote the invasion and metastasis of cancer and has been associated with poor clinical outcome.
CLDX: 28.95 (+1.08)
Celldex Therapeutics Announces Initiation of Phase 1/2 Study of Varlilumab in Combination with Ipilimumab and CDX-1401 in Metastatic Melanoma
GlobeNewswire - Mon Apr 06, 7:01AM CDT
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced the initiation of a Phase 1/2 safety pilot and expansion study examining the investigational combination of varlilumab and ipilimumab (Yervoy; Bristol-Myers Squibb) in patients with Stage III or IV metastatic melanoma. Varlilumab is Celldex's fully human monoclonal antibody that targets CD27, a critical co-stimulatory molecule in the immune activation cascade. Ipilimumab, a recombinant, human monoclonal antibody that blocks CTLA-4, is FDA approved for the treatment of unresectable or metastatic melanoma. In the Phase 2 portion of the study, patients with tumors that express NY-ESO-1 will also receive CDX-1401, Celldex's off-the-shelf antibody-based dendritic cell vaccine that targets tumors expressing the NY-ESO-1 oncoprotein.
CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21)
Roth Capital Weighs In On 5 Biotech Stocks To Watch
TipRanks - at Seeking Alpha - Mon Apr 06, 4:02AM CDT
By Sarah Roden As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to "focus on names with definitive catalysts." Though the analyst rates 15 biotech stocks,...
CRIS: 2.88 (+0.09), GNVC: 2.86 (-0.11), CLDX: 28.95 (+1.08), BLRX: 2.12 (unch), KERX: 11.52 (-0.15)
Disruptive Innovation Changing the Fight Against Cancer
Cheryl Swanson, The Motley Fool - Motley Fool - Sun Apr 05, 12:02PM CDT
We all know someone who is battling cancer. It's a terrible disease, with over 1.6 million new cases diagnosed every year in the U.S. Cancer deaths per 100,000 people have been slowly declining since 1991, but tragically, modern treatment often has...
NWBO: 8.36 (-0.39), MRK: 57.69 (+0.03), CLDX: 28.95 (+1.08), AZN: 73.35 (+0.65), XON: 44.53 (+0.36), BMY: 66.60 (-0.21), NVS: 103.45 (-0.62)
Northwest Biotherapeutics: Encouraging Survival Results In 51 Glioblastoma Multiforme Patients
Smith On Stocks - Seeking Alpha - Tue Mar 31, 8:48AM CDT
Executive Summary Northwest Biotherapeutics (NASDAQ: NWBO ) has just presented data on 51 patients whom investigators originally intended to enroll in the ongoing, critically important, 348 patients phase 3 trial of DCVax-L in newly diagnosed...
NWBO: 8.36 (-0.39), KITE: 57.56 (-1.43), CLDX: 28.95 (+1.08), JUNO: 55.72 (-0.68)
Celldex: An Immuno-Oncology Play With Monster Potential
DoconStocks - at Seeking Alpha - Mon Mar 30, 5:17PM CDT
CLDX: 28.95 (+1.08), BMY: 66.60 (-0.21)
3 Up and Coming Biotech Stocks to Watch
Keith Speights, The Motley Fool - Motley Fool - Sun Mar 29, 1:02PM CDT
Source: Ligand Pharmaceuticals How hot is biotech these days? The top two exchange trade funds focusing on biotech stocks both more than tripled the performance of the S&P 500 index over the past 12 months. That's pretty hot. You might be...
PTLA: 38.48 (-0.47), CLDX: 28.95 (+1.08), LGND: 87.71 (-0.58)
Celldex Therapeutics Has Returned 17.6% Since SmarTrend Recommendation (CLDX)
Comtex SmarTrend(R) - Tue Mar 24, 11:34AM CDT
SmarTrend identified an Uptrend for Celldex Therapeutics (NASDAQ:CLDX) on February 23rd, 2015 at $24.52. In approximately 4 weeks, Celldex Therapeutics has returned 17.64% as of today's recent price of $28.84.
CLDX: 28.95 (+1.08)
